Ogeda SA's G-protein coupled receptor (GPCR) therapy, fezolinetant (ESN364), has met its primary endpoint in a Phase IIa trial for the treatment of menopausal hot flashes – vital progress towards providing women with a rapid, non-hormonal treatment option, says the company's CEO Jean Combalbert. The positive data are also good news for Ogeda as it seeks more investment from sources outside of Belgium to advance its drug candidate into larger studies.
"Chronic use of hormone replacement therapy (HRT), estrogen-based drugs currently dominating the menopausal hot flashes market, is associated with various...